Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Rifaximin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB11 | O95342 | 5/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 4/20 | 1.00 |
| ▸ | ABCC2 | Q92887 | 4/20 | 1.00 |
| ▸ | MAPT | P10636 | 4/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 3/20 | 1.00 |
| ▸ | GAA | P10253 | 3/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 3/20 | 1.00 |
| ▸ | ABCC3 | O15438 | 3/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 2/20 | 1.00 |
| ▸ | ADRB2 | P07550 | 2/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 2/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 2/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 2/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 2/20 | 1.00 |
| ▸ | NPY1R | P25929 | 2/20 | 1.00 |
| ▸ | HTR2C | P28335 | 2/20 | 1.00 |
| ▸ | ADORA2A | P29274 | 2/20 | 1.00 |
| ▸ | BDKRB2 | P30411 | 2/20 | 1.00 |
| ▸ | AVPR2 | P30518 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rifaximin SCHEMBL16351426 | 1.00 | ABCB11 (1.00) | ABCB11ABCC4ABCC2MAPTTBXA2R | |
| Rifaximin SCHEMBL16229249 | 1.00 | ABCB11 (1.00) | ABCB11ABCC4ABCC2MAPTTBXA2R | |
| Rifaximin SCHEMBL874028 | 1.00 | ABCB11 (1.00) | ABCB11ABCC4ABCC2MAPTTBXA2R | |
| Rifaximin SCHEMBL14677545 | 1.00 | ABCB11 (1.00) | ABCB11ABCC4ABCC2MAPTTBXA2R | |
| Rifaximin SCHEMBL13897021 | 1.00 | ABCB11 (1.00) | ABCB11ABCC4ABCC2MAPTTBXA2R | |
| Rifaximin SCHEMBL23314507 | 1.00 | ABCB11 (1.00) | ABCB11ABCC4ABCC2MAPTTBXA2R | |
| Rifaximin SCHEMBL9397878 | 1.00 | ABCB11 (1.00) | ABCB11ABCC4ABCC2MAPTTBXA2R | |
| Rifaximin SCHEMBL17930616 | 1.00 | ABCB11 (1.00) | ABCB11ABCC4ABCC2MAPTTBXA2R | |
| Rifaximin SCHEMBL124067 | 1.00 | ABCB11 (1.00) | ABCB11ABCC4ABCC2MAPTTBXA2R | |
| Rifaximin SCHEMBL11956496 | 1.00 | ABCB11 (1.00) | ABCB11ABCC4ABCC2MAPTTBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 16402 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4746930-A1 | TOPICAL COMPOSITION FOR THE TREATMENT OF MUCOSAL LESIONS WITH SHORT GELLING TIME | Inmedical Therapeutics, S.L. (ES) | 2026-05-27 | — | — | EP | claimed |
| EP-4034091-B1 | RIFAXIMIN LIQUID FORMULATIONS | BAUSCH HEALTH IRELAND LTD (IE) | 2026-05-20 | — | — | EP | claimed |
| US-20260130932-A1 | NOVEL COMBINATION OF RIFAXIMIN AND CLARITHROMYCIN FOR TREATING MULTIDRUG-RESISTANT MYCOBACTERIUM ABSCESSUS | MASSACHUSETTS INST OF TECHNOLOGY (US) | 2026-05-14 | — | — | US | claimed |
| EP-4739321-A1 | PROBIOTIC COMPOSITION COMPRISING VIABLE KLEBSIELLA SP. STRAIN ARO112 AS THE ONLY INGREDIENT OR IN COMBINATION WITH SCFA PRODUCING BACTERIA | Fundação GIMM - Gulbenkian Institute for Molecular Medicine (PT) | 2026-05-13 | — | — | EP | claimed |
| CN-122028924-A | Porous carbon particles for therapy | UCL商业有限公司 | 2026-05-12 | — | — | CN | claimed |
| EP-4731232-A1 | POROUS CARBON PARTICLES FOR USE IN THERAPY | UCL Business Ltd (GB) | 2026-04-29 | — | — | EP | claimed |
| US-12611378-B2 | Targeted release rifaximin compositions | BAUSCH HEALTH IRELAND LIMITED (IE) | 2026-04-28 | — | — | US | claimed |
| US-12605484-B2 | Two-component system for the therapeutic treatment of skin lesions and production method thereof | DTECH - SOCIETÀ A RESPONSABILITÀ LIMITATA (IT) | 2026-04-21 | — | — | US | claimed |
| EP-3586131-B1 | MEASUREMENT OF HYDROGEN SULFIDE DURING BREATH TESTING | CEDARS SINAI MEDICAL CENTER (US) | 2026-04-15 | — | — | EP | claimed |
| US-20260076899-A1 | TARGETED RELEASE RIFAXIMIN COMPOSITIONS | BAUSCH HEALTH IRELAND LIMITED (IE) | 2026-03-19 | — | — | US | claimed |
| EP-0616808-B1 | Use of rifaximin and pharmaceutical compositions containing it in the treatment of gastric dyspepsia caused by helicobacter pylori | ALFA WASSERMANN SPA (IT) | 1996-09-11 | — | — | EP | claimed |
| US-5543417-A | 5 Alpha-reductase inhibitor and at least one of an antibacterial agent, a keratolytic agent or an anti-inflammatory agent | MERCK & CO., INC. (US) | 1996-08-06 | — | — | US | claimed |
| WO-1996012487-A1 | COMBINATION METHOD FOR ACNE TREATMENT | MERCK & CO., INC. (US) | 1996-05-02 | — | — | WO | claimed |
| WO-1996012817-A1 | COMBINATION METHOD FOR ACNE TREATMENT | MERCK & CO., INC. (US) | 1996-05-02 | — | — | WO | claimed |
| EP-0547294-B1 | Pharmaceutical compositions containing rifaximin for treatment of vaginal infections | ALFA WASSERMANN SPA (IT) | 1995-11-22 | — | — | EP | claimed |
| US-5352679-A | OraL administering | ALFA WASSERMANN S.P.A. (IT) | 1994-10-04 | — | — | US | claimed |
| EP-0616808-A1 | Use of rifaximin and pharmaceutical compositions containing it in the treatment of gastric dyspepsia caused by helicobacter pylori | ALFA WASSERMANN S.p.A. (IT) | 1994-09-28 | — | — | EP | claimed |
| US-5314904-A | Pharmaceutical compositions containing rifaximin for treatment of vaginal infections | ALFA WASSERMANN S.P.A. (IT) | 1994-05-24 | — | — | US | claimed |
| EP-0547294-A1 | Pharmaceutical compositions containing rifaximin for treatment of vaginal infections | ALFA WASSERMANN S.p.A. (IT) | 1993-06-23 | — | — | EP | claimed |
| EP-0222712-B1 | VETERINARY COMPOSITIONS CONTAINING ANTIMICROBIAL AGENTS, AND THEIR USE | FATRO S.p.A: (IT) | 1990-06-06 | — | — | EP | claimed |